CSD210202: A Study to Assess Nicotine Uptake From Electronic Nicotine Delivery Systems
NCT ID: NCT04751461
Last Updated: 2022-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
33 participants
INTERVENTIONAL
2021-02-23
2021-04-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess Nicotine Uptake From Electronic Nicotine Delivery Systems
NCT07323563
CSD201002: Study to Assess Nicotine Uptake From P10 Nicotine Pouches
NCT05081154
CSD201202: A Study to Assess Nicotine Uptake From Electronic Nicotine Delivery System P12
NCT05239884
CSD201201: Study to Assess Elements of Abuse Liability for Electronic Nicotine Delivery System P12
NCT05210699
CSD190401: A Study to Assess Elements of Abuse Liability for Nicotine-containing Pouch Tobacco Products
NCT04372290
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Following the Screening Visit, eligible subjects will be scheduled for a check-in and randomization visit. At the check-in and randomization visit, subjects' continued eligibility will be confirmed prior to being randomized to a product use sequence and beginning their 6 nights and 7 days of confinement.
Starting on study Day 1, subject will start a Pre-study ENDS IP Acclimation Period through Day 2. Subjects will be asked to acclimate to each of the ENDS IP at least once, while having access to their usual brand (UB) cigarettes for ad libitum use. Starting on Day 3, subjects will participate in five separate Test Sessions for nicotine PK assessment, one for each ENDS IP. For approximately a half day prior to each respective Test Session (starting on Day 2), subjects will use their assigned ENDS IP for the following day's Test Session at least twice.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Product usage order ABECD
Subjects will use each of the 5 products (ABECD) during an evaluation period, followed by a 4 hour Test Session
Product A
P0213420, a 1.8% nicotine ENDS product
Product B
P0213520, a 1.8% nicotine ENDS product
Product C
P0211220, a 1.8% nicotine ENDS product
Product D
P0211820, a 1.8% nicotine ENDS product
Product E
P0213417, a 2.4% nicotine ENDS product
Product usage order BCADE
Subjects will use each of the 5 products (BCADE) during an evaluation period, followed by a 4 hour Test Session
Product A
P0213420, a 1.8% nicotine ENDS product
Product B
P0213520, a 1.8% nicotine ENDS product
Product C
P0211220, a 1.8% nicotine ENDS product
Product D
P0211820, a 1.8% nicotine ENDS product
Product E
P0213417, a 2.4% nicotine ENDS product
Product usage order CDBEA
Subjects will use each of the 5 products (CDBEA) during an evaluation period, followed by a 4 hour Test Session
Product A
P0213420, a 1.8% nicotine ENDS product
Product B
P0213520, a 1.8% nicotine ENDS product
Product C
P0211220, a 1.8% nicotine ENDS product
Product D
P0211820, a 1.8% nicotine ENDS product
Product E
P0213417, a 2.4% nicotine ENDS product
Product usage order DECAB
Subjects will use each of the 5 products (DECAB) during an evaluation period, followed by a 4 hour Test Session
Product A
P0213420, a 1.8% nicotine ENDS product
Product B
P0213520, a 1.8% nicotine ENDS product
Product C
P0211220, a 1.8% nicotine ENDS product
Product D
P0211820, a 1.8% nicotine ENDS product
Product E
P0213417, a 2.4% nicotine ENDS product
Product usage order EADBC
Subjects will use each of the 5 products (EADBC) during an evaluation period, followed by a 4 hour Test Session
Product A
P0213420, a 1.8% nicotine ENDS product
Product B
P0213520, a 1.8% nicotine ENDS product
Product C
P0211220, a 1.8% nicotine ENDS product
Product D
P0211820, a 1.8% nicotine ENDS product
Product E
P0213417, a 2.4% nicotine ENDS product
Product usage order DCEBA
Subjects will use each of the 5 products (DCEBA) during an evaluation period, followed by a 4 hour Test Session
Product A
P0213420, a 1.8% nicotine ENDS product
Product B
P0213520, a 1.8% nicotine ENDS product
Product C
P0211220, a 1.8% nicotine ENDS product
Product D
P0211820, a 1.8% nicotine ENDS product
Product E
P0213417, a 2.4% nicotine ENDS product
Product usage order EDACB
Subjects will use each of the 5 products (EDACB) during an evaluation period, followed by a 4 hour Test Session
Product A
P0213420, a 1.8% nicotine ENDS product
Product B
P0213520, a 1.8% nicotine ENDS product
Product C
P0211220, a 1.8% nicotine ENDS product
Product D
P0211820, a 1.8% nicotine ENDS product
Product E
P0213417, a 2.4% nicotine ENDS product
Product usage order AEBDC
Subjects will use each of the 5 products (AEBDC) during an evaluation period, followed by a 4 hour Test Session
Product A
P0213420, a 1.8% nicotine ENDS product
Product B
P0213520, a 1.8% nicotine ENDS product
Product C
P0211220, a 1.8% nicotine ENDS product
Product D
P0211820, a 1.8% nicotine ENDS product
Product E
P0213417, a 2.4% nicotine ENDS product
Product usage order BACED
Subjects will use each of the 5 products (BACED) during an evaluation period, followed by a 4 hour Test Session
Product A
P0213420, a 1.8% nicotine ENDS product
Product B
P0213520, a 1.8% nicotine ENDS product
Product C
P0211220, a 1.8% nicotine ENDS product
Product D
P0211820, a 1.8% nicotine ENDS product
Product E
P0213417, a 2.4% nicotine ENDS product
Product usage order CBDAE
Subjects will use each of the 5 products (CBDAE) during an evaluation period, followed by a 4 hour Test Session
Product A
P0213420, a 1.8% nicotine ENDS product
Product B
P0213520, a 1.8% nicotine ENDS product
Product C
P0211220, a 1.8% nicotine ENDS product
Product D
P0211820, a 1.8% nicotine ENDS product
Product E
P0213417, a 2.4% nicotine ENDS product
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Product A
P0213420, a 1.8% nicotine ENDS product
Product B
P0213520, a 1.8% nicotine ENDS product
Product C
P0211220, a 1.8% nicotine ENDS product
Product D
P0211820, a 1.8% nicotine ENDS product
Product E
P0213417, a 2.4% nicotine ENDS product
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Generally healthy male or female, 21 to 60 years of age, inclusive, at the time of consent.
3. Expired breath carbon monoxide level is ≥ 10 ppm and ≤ 100 ppm at Screening.
4. Positive urine cotinine test at Screening.
5. Smokes only filtered, menthol or non-menthol combustible cigarettes, 83 mm to 100 mm in length.
6. Agrees to smoke same UB combustible cigarette throughout the study period. UB combustible cigarette is defined as the cigarette brand style currently smoked most frequently by the subject.
7. Smokes at least 10 cigarettes per day (on average) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (prior to 30 days of Screening), or clinical study participation (prior to 30 days of Screening) will be allowed at the discretion of the Principal Investigator (PI).
8. Willing to use only UB combustible cigarette and ENDS during the study period.
9. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to each Test Session.
10. Females must be willing to use a form of contraception acceptable to the PI from the time of signing informed consent until End-of-Study.
11. Agrees to in-clinic confinement of 7 days and 6 nights.
Exclusion Criteria
2. History, presence of, or clinical laboratory test results indicating diabetes.
3. Systolic blood pressure of \> 160 mmHg or a diastolic blood pressure of \> 95mmHg, measured after being seated for five minutes.
4. Weight of ≤ 110 pounds.
5. Hemoglobin level is \< 12.5 for females or \<13.0 for males g/dL at Screening.
6. Scheduled treatment for asthma currently or within the past consecutive 12 months prior to the Screening Visit. As-needed treatment, such as inhalers, may be included at the PI's discretion pending approval from the Medical Monitor.
7. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).
8. Any history of cancer, except for primary cancers of skin such as localized basal cell/squamous cell carcinoma that has been surgically and/or cryogenically removed.
9. Use of an ENDS or tobacco or nicotine-containing products other than cigarettes (e.g., lozenges, moist snuff) within (≤) 30 days prior to Screening.
10. Use of any medication or substance that aids in smoking cessation, including but not limited to any NRT (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), or lobelia extract within (≤) 30 days prior to the signing of informed consent.
11. History or presence of bleeding or clotting disorders.
12. Any use of anticoagulants or aspirin (≥ 325 mg/day).
13. Whole blood donation within 8 weeks (≤ 56 days) prior to the signing of informed consent.
14. Plasma donation within (≤) 7 days prior to the signing of informed consent.
15. Plans to donate whole blood or plasma prior to Enrollment and Study Day 1.
16. Participation in another clinical trial within (≤) 30 days prior to the signing of informed consent. The 30-day window for each subject will be derived from the date of the last study event in the previous study to the time of signing the ICF in the current study.
17. Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.
18. Individuals ≥ 35 years of age currently using systemic, estrogen-containing contraception or hormone replacement therapy.
19. A positive urine drug screen without evidence of prescribed corresponding concomitant medication(s) at Screening or Day 1.
20. Postpones a decision to quit using tobacco- or nicotine-containing products in order to participate in this study or a previous attempt within (≤) 30 days prior to the signing of the ICF.
21. Drinks more than 21 servings of alcoholic beverages per week or has a positive alcohol breathalyzer result at Screening or Day 1.
22. Employed by a tobacco or nicotine company, the study site, or handles tobacco- or nicotine-containing products as part of their job.
23. Determined by the PI to be inappropriate for this study. \*Subjects will be advised against scheduling of whole blood or plasma donation following study completion for at least 7 days.
21 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RAI Services Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jason Hong, MD
Role: STUDY_DIRECTOR
RAIS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AMR Knoxville
Knoxville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CSD210202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.